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CARTILAGE MARKERS AND THEIR ASSOCIATION WITH
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Purpose: The development and validation of biochemical mark-
ers for osteoarthritis may accelerate the pace of therapeutic
development. We used data from a longitudinal observation
study to determine if markers of cartilage turnover could serve
as predictors of cartilage loss on MRI.
Methods: We conducted a cross sectional analysis of data from
the Boston Osteoarthritis of the Knee Study (BOKS); a com-
pleted natural history study of knee osteoarthritis. All subjects in
the study met ACR criteria for knee OA. Knee MR images were
scored for cartilage loss using the WORMS semi-quantitative
grading scheme. Within the BOKS population 80 subjects with
cartilage loss and 80 subjects without cartilage loss were se-
lected for the purposes of this nested case control study. We
assessed the baseline levels of cartilage degradation and syn-
thesis products (Col2:3/4Cshort (C1, 2C) with Col2:3/4Clongmono
(C2C); Col II C- telopeptide (Col2CTx); C-propeptide of type II
collagen; Aggrecan 846 Epitope; COMP). We performed a logis-
tic regression to examine the relation of levels of each biomarker
to the risk of cartilage loss in any plate. Cartilage loss was
defined as an increase in cartilage score in any of the plates
previously mentioned. Considering that the risk profiles of carti-
lage loss and magnitude of effect of a particular biomarker on
cartilage loss may be different between men and women, we first
conducted separate analyses for each sex. As the magnitude of
effect of biomarkers was similar for men and women, we then
performed the analysis adjusting for gender, age and BMI.
Results: 160 persons with symptomatic knee OA were as-
sessed. At baseline the mean (SD) age was 67 (9) years
and 54% were male. 76% of the subjects had radiographic
tibiofemoral osteoarthritis (K&L ≥ 2) whilst the remainder had
patellofemoral OA. The results of the logistic regression for uni-
variate biomarker predictors with the outcome cartilage loss in
any plate are displayed in the table. With the exception of COMP
none of the other biomarkers were statistically significant predic-
tors of cartilage loss. For COMP a 1 standard deviation increase
in COMP increased the odds of subsequent cartilage loss 1.49
times (95%CI 1.04-2.14). The c statistic for the univariate as-
sociation was 0.60. After adjusting the analysis for COMP for
Standardized cartilage biomarkers and their respective prediction of subsequent
MRI cartilage loss
Unadjusted AUC p value Adjusted (Age,s ex, BMI)
OR (95% CI) OR (95% CI)
COMP 1.49 (1.04-2.14) 0.60 0.03 1.51 (1.04-2.18)
846 Epitope 0.95 (0.66-1.35) 0.53 0.76 0.98 (0.68-1.41)
CPII 1.08 (0.78-1.52) 0.53 0.64 1.07 (0.76-1.51)
C1,2C 0.85 (0.61-1.19) 0.55 0.35 0.87 (0.62-1.23)
Col2CTX/Cr ratio 1.21 (0.78-1.89) 0.49 0.39 1.18 (0.76-1.83)
C2C 0.69 (0.46-1.04) 0.58 0.08 0.70 (0.46-1.05)
age, sex and BMI the odds for cartilage loss was 1.51 (95%
CI1.04-2.18).
None of the ratios of uncoupling of biomarker predictors facili-
tated prediction of cartilage loss.
Conclusions: Increased COMP levels predict subsequent car-
tilage loss on MRI. The other biochemical markers of cartilage
synthesis and degradation do not facilitate prediction of cartilage
loss. With the exception of COMP if changes in cartilage turnover
in persons with symptomatic knee OA are associated with carti-
lage loss, they do not appear to affect systemic biomarker levels.
Based on these data we would not advocate their use as markers
to predict progression in persons with symptomatic knee OA.
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Purpose: Inflammation may contribute to progression of os-
teoarthritis (OA). Therefore, we investigated whether variations
in the innate ex vivo production of interleukin (IL)-1β, tumor
necrosis factor (TNF)-α, IL-1 receptor antagonist (Ra) and IL-10
in whole blood assays upon lipopolysaccharide (LPS) stimulation
is associated with the radiological progression of knee OA.
Methods: 89 participants of the GARP (Genetics, ARthrosis and
Progression) prospective cohort study with symptomatic OA of
the knee were included. Standardised posteroanterior weight-
bearing radiographs of both knees were obtained at baseline
and after 24 months using the non-fluoroscopic fixed-flexion pro-
tocol. Medial and lateral tibiofemoral joint space narrowing (JSN)
of both knees were graded (0-3) with the OARSI atlas. Radio-
graphs were read in pairs without knowledge of the chronology.
Radiological progression was defined as an increase of at least 1
score in JSN total scores. Whole-blood samples were stimulated
with LPS (10 ng/ml). Cytokines in the supernatants were mea-
sured by enzyme-linked immunosorbent assay. The relative risk
(RR) of progression of OA in relation to quartiles of innate ex vivo
production of IL-1β, TNF-α, IL-1 Ra and IL-10 were calculated
and are reported with 95% confidence intervals (CI95) computed
using robust standard errors to take into account the intrafamily
effect.
Results: Progression of JSN was present in 29 (33.7%) of the 86
followed patients after two years. The mean production of IL-1β
and IL-1Ra was not different in patients with JSN progression
compared to patients without. In patients with JSN progression,
the mean production of TNF-α was 1.11 pg/ml higher (CI95
1.03-1.22) and of IL-10 was 1.10 pg/ml higher (CI95 1.01-1.20)
compared to patients without JSN progression. Subjects in the
highest quartile of TNF-α production had a 6-fold increased risk
of JSN progression (age, sex and body mass index adjusted
RR 6.1, CI95 1.4-9.8) and subjects in the highest quartile of
IL-10 production had a 4-fold increased risk of JSN progression
(age, sex and body mass index adjusted RR 4.3, CI95 1.7-6.2),
both in comparison with those subjects in the lowest quartile. No
significant associations were found between variations in IL-1β
and IL-1Ra production and JSN progression.
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Conclusions: The innate capacity to produce TNF-α and IL-10
upon LPS stimulation contributes to radiological progression of
knee OA, even over a relative short follow-up period of two years.
This finding suggests that innate production of TNF-α and IL-10
play a role in OA progression, which if confirmed implies that
cytokines such as TNF-α could be pathophysiological targets for
OA therapy.
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REPLACEMENT
M. Deberg1, A. Labasse1, C. Sanchez1, E. Quettier2,
J.-E. Dubuc2, A. Bosseloir3, Y. Henrotin1
1University of Liège, Liège, Belgium, 2Hospital Princess Paola,
Marche-en-Famenne, Belgium, 3Zentech SA, Liège, Belgium
Purpose: To determine Coll 2-1 level, a peptide of type II colla-
gen triple helix, its nitrated form (Coll 2-1 NO2) and myeloperox-
ydase (MPO) in serum of patients with knee or hip osteoarthritis
(OA) before the surgery, three months and one year after knee
or hip replacement.
Methods: Coll 2-1, Coll 2-1 NO2 and MPO were measured by
specific immunoassays in 83 asymptomatic aged subjects and
in patients with knee (82) or hip (53) OA candidates for joint
replacement. Sera were taken the day before surgery, three
months and one year after hip or knee replacement. Coll 2-1 and
Coll 2-1 NO2 immunohistochemistry was performed on biopsies
removed from cartilage lesions and surrounding area.
Results: Immunostainings with Coll 2-1 and Coll 2-1 NO2 la-
belled extracellular matrix of fibrillated cartilage but not that of
neighbouring area. Before surgery, Coll 2-1, Coll 2-1 NO2 and
MPO levels were higher in serum of OA patients than in asymp-
tomatic aged subjects (Coll 2-1: p<0.001; Coll 2-1 NO2: p<0.001
and MPO: p<0.001). Three months after joint replacement, Coll
2-1 and MPO serum levels were decreased (p<0.001) and even
reached the control values for Coll 2-1. In contrast, Coll 2-1 NO2
levels remained elevated. At one year follow-up, Coll 2-1 levels
remained to the control values, MPO levels were similar to those
measured at 3 months, and Coll 2-1 NO2 levels were unchanged
and comparable to the pre-surgery values. However, in patients
with pre-surgery values above the median (more than 0.42 nM),
Coll 2-1 NO2 levels significantly and progressively decreased
over one-year [at month 3 median: 0.56 nM (min: 0.14 nM-max:
4.05 nM; after one year median: 0.46 nM (min: 0.21 nM-3.66 nM]
compared to the pre-surgery values [median: 0.72 nM (min: 0.43
nM-max: 4.21 nM)].
Conclusions: These findings suggest that Coll 2-1 is a relevant
marker for the detection of late structural changes in OA patients.
Furthermore, the normalization of Coll 2-1 levels three months
after surgery indicates that Coll 2-1 is a disease-specific marker
which is sensitive to the structural changes occurring in one
single joint. Interestingly, MPO and Coll 2-1 NO2 are increased
in OA patients indicating that an oxidative stress occurs in the
late stage of the disease.
A3 – Table 1. Serum levels [median (range)] of Coll 2-1, Coll 2-1 NO2 and MPO in asymptomatic subjects and OA patients.
Asymptomatic subjects OA subjects
Before surgery 3 months after joint replacement 1 year after joint replacement
COLL 2-1 (nM) 123.69 (37.60-284.09) 156.84 (45.77-460.80) 119.58 (17.00-250.19) 114.61 (24.38-303.82)
COLL 2-1 NO2 (nM) 0.26 (<0.03-1.66) 0.42 (0.10-4.21) 0.45 (<0.03-4.05) 0.42 (0.21-3.66)
MPO (ng/ml) 67.00 (0.00-212.00) 153.73 (0.00-1213.00) 92.00 (0.00-859.00) 98.70 (39.90-789.60)
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REARFOOT MOBILITY DETERMINES IF VALGUS
WEDGED ORTHOSES REDUCE KNEE ADDUCTION
MOMENTS IN MEDIAL KNEE OSTEOARTHRITIS (OA)
R. Lidtke1, B. Goker2, C. Meuhleman1, M. Wimmer1,
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Purpose: It has previously been demonstrated that patients with
medial knee OA have increased loads across the medial knee,
and we have shown that valgus posted foot orthoses have an ef-
fect on these knee adduction moments (AddM). This study aimed
to determine whether the reductions in AddM in the presence of
the wedge orthoses are related to frontal motion and position of
the rearfoot in symptomatic medial compartment knee OA.
Methods: 40 subjects (63.4±9.9, mean±S.D, years of age, BMI
of 28.5±4.4) with medial knee OA (symptomatic OA according
to the ACR Clinical Criteria for OA, radiographic OA of Kellgren-
Lawrence (K-L) grades 2-3, predominantly medial disease, and
ambulatory knee pain ≥20mm on a 100mm VAS scale) were
recruited from an ongoing double-blind randomized controlled
trial [NLM Identifier: NCT00078453]. Exclusions included symp-
tomatic arthritis of the hip, ankle, or foot; structural foot pathology;
or any inflammatory arthritis. WOMAC site-specific surveys for
each knee and weight-bearing AP lower extremity X-rays were
obtained. Radiographic alignment of the rearfoot and lower leg
along with anthropometric measurements were obtained by a
blinded experienced clinician with the subject standing in two dif-
ferent stance-foot positions. Subjects were randomized into two
groups, one consisting of treatment with custom molded foot or-
thosis posted to 7 degrees everted (valgus wedge) and the other
with custom molded foot orthosis with no post (neutral). Kine-
matic and kinetic gait data were obtained as previously described
using an optoelectronic system (Qualysis, Gothenburg, Sweden)
and a multicomponent force plate (Bertec, Columbus, OH). The
subjects wore the orthoses daily for three months and the gait
tests were repeated. For statistical evaluation, subjects were di-
chotomized into "high mobility" with a rearfoot range of motion
(ROM)>8° (12.4°±4.0) and "low mobility" ROM <8° (4.9°±3.1),
and each treatment group was analyzed using ANOVA. Changes
in the radiographic angles were compared between positions and
groups and analyzed with Pearson’s correlation coefficient and
ANOVA.
Results: At 3 months, among the wedge-treated subjects there
was a 12% reduction in knee AddM for those that were "high mo-
bility," i.e., had greater frontal plane rearfoot motion, compared to
those that were "low mobility" (p=0.001); in contrast, the neutral
control group had no change in AddM regardless of frontal plane
motion. In addition, the "low mobility" group did not have signif-
icant reductions in AddM, even when treated with the wedge.
No correlation was demonstrated between the reduction in mo-
ments and either WOMAC pain severity or radiographic severity
as determined by K-L grade. The changes in the radiographic
alignment demonstrated that a wider stance position resulted
in less varus of the rearfoot and lower leg and confirmed the
dichotomization of the groups with a strong correlation between
changes in radiographic alignment and anthropometric measure-
ments (R2=0.69 p<0.001). The changes in lower extremity radio-
graphic alignment were also correlated to the reduction of knee
